| Autor: |
Arango, Celso, Buitelaar, Jan K, Fegert, Jörg M, Olivier, Valérie, Pénélaud, Pierre-François, Marx, Ute, Chimits, Damien, Falissard, Bruno, Barylnik, Julia, Birdeanu, Laura, Bosch, Gert P, Boychevskaya, Julia, Boyev, Igor, Bugán, Enikõ, Bukhanovskaya, Olga, Chaban, Oleg, Dobrescu, Iuliana, Feller, Gábor, Flisiak-Antonijczuk, Halina, Gácser, Magdolna, Grigorieva, Elena, Holttinen, Timo, Ivanovic-Kovacevic, Svetlana, Kapornai, Krisztina, Kasimova, Lala, Martsenkovsky, Igor, Maruta, Nataliya O, Matican, Mirela, Matkovska, Tetiana, Melnyk, Ellina, Milovancevic, Milica Pejovic, Mostova, Olha, Nagy, Peter, Nussbaum, Laura, Petrov, Petar, Pietraszczyk-Kedziora, Bozena, Polnareva, Nadia, Predescu, Elena, Razsolkova, Vladislava, Rybakowski, Filip, Rymsha, Sofiia, Schrönen, Juan P, Shigashov, Dmitrii, Skrypnikov, Andrii, Stankovic, Miodrag, Stevanovic, Dejan, Timonen, Markku, Väänänen, Juha-Matti, van der Westhuizen, Jannie, van Niekerk, Gert, Venger, Olena, Vladimirovich, Evgeniy, Voloshchuk, Anatolii, Wolańczyk, Tomasz |
| Zdroj: |
The Lancet Psychiatry; February 2022, Vol. 9 Issue: 2 p113-124, 12p |
| Abstrakt: |
Major depressive disorder is a severe illness that frequently manifests before the age of 18 years, often recurring later in life. Paediatric medical treatment options are scarce. The melatonin receptor agonist and 5-hydroxytryptamine2Creceptor antagonist agomelatine is used to treat adults, and could offer a new therapeutic option for paediatric patients. Therefore, we aimed to investigate the short-term antidepressant efficacy and safety of agomelatine in children and adolescents with major depressive disorder. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
